Aeglea Bio Therapeutics Inc expected to post a loss of 84 cents a share - Earnings Preview

Spyre Therapeutics

30/10/2023 14:19

* Aeglea Bio Therapeutics Inc  AGLE.OQ   AGLE.O  is expected
to show a fall in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Aeglea Bio
Therapeutics
Inc is for a loss of 84 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 9.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Aeglea Bio
Therapeutics Inc is $17.75​, above​ its last closing price
of $10.66. ​​​

This summary was machine generated October 30 at 14:19 GMT.  All
figures in US dollars  unless otherwise stated